1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide → HCID 178467055, 화합물
반응식
[NH2:1][C:2]1[N:7]2[N:8]=[CH:9][C:10]([C:11]3[CH:12]=[N:13][C:14]([C:17]4[CH:22]=[CH:21][CH:20]=[CH:19][CH:18]=4)=[CH:15][CH:16]=3)=[C:6]2[N:5]=[C:4]([N:23]2[CH2:29][CH:28]3[NH:30][CH:25]([CH2:26][CH2:27]3)[CH2:24]2)[C:3]=1[C:31](=[O:33])[CH3:32].[N:34]1[N:35]=[C:36]([C:39](O)=[O:40])[NH:37][CH:38]=1.CCN=C=NCCCN(C)C.C1C=CC2N(O)N=NC=2C=1.CCN(C(C)C)C(C)C>CN(C=O)C>[N:34]1[N:35]=[C:36]([C:39]([N:30]2[CH:28]3[CH2:27][CH2:26][CH:25]2[CH2:24][N:23]([C:4]2[C:3]([C:31](=[O:33])[CH3:32])=[C:2]([NH2:1])[N:7]4[N:8]=[CH:9][C:10]([C:11]5[CH:12]=[N:13][C:14]([C:17]6[CH:18]=[CH:19][CH:20]=[CH:21][CH:22]=6)=[CH:15][CH:16]=5)=[C:6]4[N:5]=2)[CH2:29]3)=[O:40])[NH:37][CH:38]=1참가 물질
7
반응물 5
생성물 1
시약·촉매·용매 1
실험 절차
A mixture of 1-(7-amino-5-(3,8-diazabicyclo[3.2.1]octan-3-yl)-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl)ethanone (11 mg, 0.025 mmol), 4H-1,2,4-triazole-3-carboxylic acid (3.1 mg, 0.027 mmol), EDCI (9.5 mg, 0.05 mmol), HOBt (6.75 mg, 0.05 mmol) and DIEA (26 ul, 0.15 mmol) in DMF (1 ml) was stirred at room temperature overnight. Purification with prep-LC provided 1-(5-(8-(4H-1,2,4-triazole-3-carbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-amino-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl)ethanone, LCMS tR=3.31 Min (10 min run, UV 254 nm). Mass calculated for M+H 535.2, observed LC/MS m/z 534.95 (M+H).
후처리
- customPurification
출처 및 근거
- ORD 기록
- ord-44f60645d2604f90b0446f6b219da8fb
- 출처 데이터셋
- uspto-grants-2016_01
- 특허 번호
- US09227971B2
반응 노트
불러오는 중…